Fresenius Kidney Care Caroline Street is a medicare approved dialysis facility center in Baltimore, Maryland and it has 21 dialysis stations. It is located in Baltimore City county at 407 North Caroline Street, Baltimore, MD, 21231. You can reach out to the office of Fresenius Kidney Care Caroline Street at (410) 537-5830. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fresenius Kidney Care Caroline Street has the following ownership type - Profit. It was first certified by medicare in June, 2016. The medicare id for this facility is 212707 and it accepts patients under medicare ESRD program.
| Name | Fresenius Kidney Care Caroline Street |
|---|---|
| Location | 407 North Caroline Street, Baltimore, Maryland |
| No. of Dialysis Stations | 21 |
| Medicare ID | 212707 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 407 North Caroline Street, Baltimore, Maryland, 21231 | |
| (410) 537-5830 | |
News Archive
MicroBiome TherapeuticsTM LLC, today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
Breast cancer is the most frequent type of cancer in women and currently accounts for 29% of all new cancer cases in the U.S. Wide-ranging mammography screening programs have been set up for early diagnosis. However, even if two physicians assess the x-rays, which is the usual procedure in Europe, this often leads to wrong decisions: about 20% of patients with cancer are diagnosed as being cancer-free, whereas about 20% of cancer-free patients are diagnosed with cancer.
The brains of one species of mouse actually shrink during the winter, causing the mice to have more difficulty with some types of learning, a new study found.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
› Verified 9 days ago
| NPI Number | 1689035693 |
| Organization Name | Fresenius Kidney Care Caroline Street |
| Doing Business As | Baltimore County Dialysis, Llc |
| Address | 409 N Caroline St Baltimore, Maryland, 21231 |
| Phone Number | (410) 537-5830 |
News Archive
MicroBiome TherapeuticsTM LLC, today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
Breast cancer is the most frequent type of cancer in women and currently accounts for 29% of all new cancer cases in the U.S. Wide-ranging mammography screening programs have been set up for early diagnosis. However, even if two physicians assess the x-rays, which is the usual procedure in Europe, this often leads to wrong decisions: about 20% of patients with cancer are diagnosed as being cancer-free, whereas about 20% of cancer-free patients are diagnosed with cancer.
The brains of one species of mouse actually shrink during the winter, causing the mice to have more difficulty with some types of learning, a new study found.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 70 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 37 |
News Archive
MicroBiome TherapeuticsTM LLC, today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
Breast cancer is the most frequent type of cancer in women and currently accounts for 29% of all new cancer cases in the U.S. Wide-ranging mammography screening programs have been set up for early diagnosis. However, even if two physicians assess the x-rays, which is the usual procedure in Europe, this often leads to wrong decisions: about 20% of patients with cancer are diagnosed as being cancer-free, whereas about 20% of cancer-free patients are diagnosed with cancer.
The brains of one species of mouse actually shrink during the winter, causing the mice to have more difficulty with some types of learning, a new study found.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 114 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1063 |
| Percentage of adult patients getting regular hemodialysis at the center | 96 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
MicroBiome TherapeuticsTM LLC, today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
Breast cancer is the most frequent type of cancer in women and currently accounts for 29% of all new cancer cases in the U.S. Wide-ranging mammography screening programs have been set up for early diagnosis. However, even if two physicians assess the x-rays, which is the usual procedure in Europe, this often leads to wrong decisions: about 20% of patients with cancer are diagnosed as being cancer-free, whereas about 20% of cancer-free patients are diagnosed with cancer.
The brains of one species of mouse actually shrink during the winter, causing the mice to have more difficulty with some types of learning, a new study found.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
› Verified 9 days ago
| Adult patients getting regular peritoneal dialysis at the center | 14 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 112 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 80 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
MicroBiome TherapeuticsTM LLC, today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
Breast cancer is the most frequent type of cancer in women and currently accounts for 29% of all new cancer cases in the U.S. Wide-ranging mammography screening programs have been set up for early diagnosis. However, even if two physicians assess the x-rays, which is the usual procedure in Europe, this often leads to wrong decisions: about 20% of patients with cancer are diagnosed as being cancer-free, whereas about 20% of cancer-free patients are diagnosed with cancer.
The brains of one species of mouse actually shrink during the winter, causing the mice to have more difficulty with some types of learning, a new study found.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fresenius Kidney Care Caroline Street with elevated calcium levels.
| Patients with hypercalcemia | 128 |
| Hypercalcemia patient months | 1187 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 132 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 26 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 32 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 19 |
| Patients with Serumphosphor greater than 7 mg/dL | 12 |
News Archive
MicroBiome TherapeuticsTM LLC, today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
Breast cancer is the most frequent type of cancer in women and currently accounts for 29% of all new cancer cases in the U.S. Wide-ranging mammography screening programs have been set up for early diagnosis. However, even if two physicians assess the x-rays, which is the usual procedure in Europe, this often leads to wrong decisions: about 20% of patients with cancer are diagnosed as being cancer-free, whereas about 20% of cancer-free patients are diagnosed with cancer.
The brains of one species of mouse actually shrink during the winter, causing the mice to have more difficulty with some types of learning, a new study found.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 104 |
| Patient months included in arterial venous fistula and catheter summaries | 831 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 64 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 8 |
News Archive
MicroBiome TherapeuticsTM LLC, today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
Breast cancer is the most frequent type of cancer in women and currently accounts for 29% of all new cancer cases in the U.S. Wide-ranging mammography screening programs have been set up for early diagnosis. However, even if two physicians assess the x-rays, which is the usual procedure in Europe, this often leads to wrong decisions: about 20% of patients with cancer are diagnosed as being cancer-free, whereas about 20% of cancer-free patients are diagnosed with cancer.
The brains of one species of mouse actually shrink during the winter, causing the mice to have more difficulty with some types of learning, a new study found.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 75 |
| Hospitalization Rate in facility | 140.7 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 310.5 |
| Hospitalization Rate: Lower Confidence Limit | 67.9 |
News Archive
MicroBiome TherapeuticsTM LLC, today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
Breast cancer is the most frequent type of cancer in women and currently accounts for 29% of all new cancer cases in the U.S. Wide-ranging mammography screening programs have been set up for early diagnosis. However, even if two physicians assess the x-rays, which is the usual procedure in Europe, this often leads to wrong decisions: about 20% of patients with cancer are diagnosed as being cancer-free, whereas about 20% of cancer-free patients are diagnosed with cancer.
The brains of one species of mouse actually shrink during the winter, causing the mice to have more difficulty with some types of learning, a new study found.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Fresenius Kidney Care Caroline Street were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 20.1 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 33.6 |
| Readmission Rate: Lower Confidence Limit | 9.9 |
News Archive
MicroBiome TherapeuticsTM LLC, today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.
The National High Magnetic Field Laboratory at Florida State University is planning to build a state-of-the-art magnet system that will transform the study of complex environmental and biological samples. A better understanding of fossil and biological fuels, for example, could lead to applications for reducing carbon emissions and the development of new, sustainable fuels.
Breast cancer is the most frequent type of cancer in women and currently accounts for 29% of all new cancer cases in the U.S. Wide-ranging mammography screening programs have been set up for early diagnosis. However, even if two physicians assess the x-rays, which is the usual procedure in Europe, this often leads to wrong decisions: about 20% of patients with cancer are diagnosed as being cancer-free, whereas about 20% of cancer-free patients are diagnosed with cancer.
The brains of one species of mouse actually shrink during the winter, causing the mice to have more difficulty with some types of learning, a new study found.
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
› Verified 9 days ago